May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Association of Mortality With AMD, Cataract and High-Dose Antioxidants and Zinc After Long-Term Follow-Up in the Age-Related Eye Disease Study
Author Affiliations & Notes
  • T. E. Clemons
    Statistics, EMMES Corporation, Rockville, Maryland
  • E. Y. Chew
    National Eye Institute, NIH, Bethesda, Maryland
  • R. C. Milton
    Statistics, EMMES Corporation, Rockville, Maryland
  • AREDS Research Group
    Statistics, EMMES Corporation, Rockville, Maryland
  • Footnotes
    Commercial Relationships  T.E. Clemons, None; E.Y. Chew, None; R.C. Milton, None.
  • Footnotes
    Support  NEI\NIH\DHHS Contracts
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 2458. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. E. Clemons, E. Y. Chew, R. C. Milton, AREDS Research Group; Association of Mortality With AMD, Cataract and High-Dose Antioxidants and Zinc After Long-Term Follow-Up in the Age-Related Eye Disease Study. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2458. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To assess retrospectively the association of late age-related macular degeneration (AMD), lens opacity, cataract surgery, visual acuity or high-doses of antioxidants and zinc with mortality in the Age-Related Eye Disease Study (AREDS) after a median 10.5 years of follow-up.

Methods: : Color fundus photographs taken at baseline were used to classify participants into one of four AMD categories: Category 1 - Few if any drusen; Category 2 - Extensive small drusen or at least 1 intermediate size druse; Category 3 - Extensive intermediate drusen or at least 1 large druse; and Category 4 - Advanced AMD (AAMD) in one eye. Lens photographs were taken at baseline to assess the presence and severity of nuclear, cortical and posterior subcapsular lens opacities using the AREDS Cataract Classification. A history of cataract surgery at baseline was also collected. Baseline refraction and measurement of visual acuity were performed and each participant was classified into 1 of 2 visual acuity groups: 20/40 or better in both eyes versus worse than 20/40 in one eye. AREDS included a randomized clinical trial that evaluated the effect of high doses of selected supplements (vitamin C, 500 mg; vitamin E, 400 IU; beta-carotene, 15 mg; zinc-oxide, 80 mg; and cupric oxide, 2 mg) on the incidence and progression of the AAMD and cataract. The primary outcome was all cause mortality. Cause-specific mortality was based on ICD9 or ICD10 codes. Age- and gender-adjusted Cox-proportional hazards models were created with AMD category at baseline as the independent variable. Significant health status indicators were added to models that examined the effect of the ocular characteristics on mortality.

Results: : During a median follow-up of 10.5 years, 1057 (22%) of 4753 AREDS participants died. After adjusting for age, gender, and factors associated with mortality, poorer survival was associated with AAMD (risk ratio [RR], 1.27; 95% confidence interval [CI], 1.05 - 1.54), visual acuity worse than 20/40 in at least one eye (RR, 1.27; 95% CI, 1.10 - 1.47), nuclear cataract (RR, 1.29, 95% CI, 1.10 - 1.52), and cataract surgery (RR, 1.30, 95% CI 1.05 - 1.61). Participants randomly assigned to zinc at baseline had lower mortality compared to those not randomized to zinc (RR, 0.83, 95% CI 0.73 - 0.95).

Conclusions: : Long-term follow-up of AREDS participants confirm that AMD, cataract and visual acuity is related to decreased survival. The study provides additional evidence of improved survival in individuals randomly assigned to zinc.

Clinical Trial: : www.clinicaltrials.gov NCT00000145

Keywords: age-related macular degeneration • clinical (human) or epidemiologic studies: risk factor assessment • visual acuity 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×